HRP20231650T1 - Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka - Google Patents
Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka Download PDFInfo
- Publication number
- HRP20231650T1 HRP20231650T1 HRP20231650TT HRP20231650T HRP20231650T1 HR P20231650 T1 HRP20231650 T1 HR P20231650T1 HR P20231650T T HRP20231650T T HR P20231650TT HR P20231650 T HRP20231650 T HR P20231650T HR P20231650 T1 HRP20231650 T1 HR P20231650T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide
- immune checkpoint
- checkpoint inhibitor
- sequence
- cocktail
- Prior art date
Links
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 title claims 30
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 title claims 30
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 title claims 30
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 title claims 30
- 206010028980 Neoplasm Diseases 0.000 title claims 3
- 201000011510 cancer Diseases 0.000 title claims 3
- 229960005486 vaccine Drugs 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims 43
- 102000004196 processed proteins & peptides Human genes 0.000 claims 43
- 108090000765 processed proteins & peptides Proteins 0.000 claims 43
- 239000012634 fragment Substances 0.000 claims 32
- 230000002163 immunogen Effects 0.000 claims 18
- 239000000427 antigen Substances 0.000 claims 14
- 102000036639 antigens Human genes 0.000 claims 14
- 108091007433 antigens Proteins 0.000 claims 14
- 150000001413 amino acids Chemical class 0.000 claims 12
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 6
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 2
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 229950009791 durvalumab Drugs 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 229960005386 ipilimumab Drugs 0.000 claims 2
- 229960003301 nivolumab Drugs 0.000 claims 2
- 238000002255 vaccination Methods 0.000 claims 2
- 229960003852 atezolizumab Drugs 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 229960002621 pembrolizumab Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 229950007217 tremelimumab Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001148—Regulators of development
- A61K39/00115—Apoptosis related proteins, e.g. survivin or livin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001157—Telomerase or TERT [telomerase reverse transcriptase]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16172760 | 2016-06-02 | ||
| PCT/EP2017/063589 WO2017207814A1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
| EP17729078.0A EP3463436B1 (en) | 2016-06-02 | 2017-06-02 | A vaccine in combination with an immune checkpoint inhibitor for use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20231650T1 true HRP20231650T1 (hr) | 2024-05-10 |
Family
ID=56132759
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20231650TT HRP20231650T1 (hr) | 2016-06-02 | 2017-06-02 | Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11419927B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4253419A3 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7321709B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017275782B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3026172A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK3463436T3 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2965957T3 (cg-RX-API-DMAC7.html) |
| FI (1) | FI3463436T3 (cg-RX-API-DMAC7.html) |
| HR (1) | HRP20231650T1 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE065176T2 (cg-RX-API-DMAC7.html) |
| LT (1) | LT3463436T (cg-RX-API-DMAC7.html) |
| PL (1) | PL3463436T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT3463436T (cg-RX-API-DMAC7.html) |
| RS (1) | RS65007B1 (cg-RX-API-DMAC7.html) |
| SI (1) | SI3463436T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017207814A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130024888A (ko) | 2010-02-16 | 2013-03-08 | 오슬로 유니버시티 하스피탈 에이치에프 | 폴리펩티드 |
| ES2965957T3 (es) | 2016-06-02 | 2024-04-17 | Ultimovacs Asa | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer |
| GB201803178D0 (en) | 2018-02-27 | 2018-04-11 | Univ Oslo Hf | Specific binding molecules for htert |
| TWI805792B (zh) * | 2018-06-29 | 2023-06-21 | 日商大鵬藥品工業股份有限公司 | 抗腫瘤劑及其評估方法 |
| EP4351634A2 (en) | 2021-06-09 | 2024-04-17 | Ultimovacs AB | A conjugate |
| WO2024083866A1 (en) | 2022-10-17 | 2024-04-25 | Ultimovacs Asa | Cancer treatment |
| WO2024126758A2 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A nucleic acid molecule and a chimeric polypeptide |
| WO2024126737A1 (en) | 2022-12-14 | 2024-06-20 | Ultimovacs Ab | A core and a conjugate |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU784062B2 (en) | 1999-08-23 | 2006-01-19 | Dana-Farber Cancer Institute, Inc. | Novel B7-4 molecules and uses therefor |
| CA3016482A1 (en) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | B7-h1, a novel immunoregulatory molecule |
| WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
| JP4511943B2 (ja) | 2002-12-23 | 2010-07-28 | ワイス エルエルシー | Ｐｄ−１に対する抗体およびその使用 |
| EP3530736A3 (en) | 2005-05-09 | 2019-11-06 | ONO Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| KR101888321B1 (ko) | 2005-07-01 | 2018-08-13 | 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체 |
| EP2007423A2 (en) | 2006-04-05 | 2008-12-31 | Pfizer Products Incorporated | Ctla4 antibody combination therapy |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| TWI605828B (zh) | 2008-12-09 | 2017-11-21 | 建南德克公司 | 抗ｐｄ-ｌ１抗體及其於增進ｔ細胞功能之用途 |
| KR20130024888A (ko) | 2010-02-16 | 2013-03-08 | 오슬로 유니버시티 하스피탈 에이치에프 | 폴리펩티드 |
| ES2616258T3 (es) | 2010-03-15 | 2017-06-12 | Academisch Ziekenhuis Leiden H.O.D.N. Lumc | Péptidos, conjugados y métodos para aumentar la inmunogenicidad de una vacuna |
| WO2012037551A2 (en) | 2010-09-17 | 2012-03-22 | Irx Therapeutics, Inc. | Primary cell-derived biologic and wt1 synthetic long peptide vaccine |
| HK1212237A1 (en) | 2012-08-31 | 2016-06-10 | University Of Virginia Patent Foundation | Target peptides for immunotherapy and diagnostics |
| GB201223386D0 (en) | 2012-12-24 | 2013-02-06 | Immune Targeting Systems Its Ltd | Vaccine |
| MX385338B (es) * | 2013-02-22 | 2025-03-18 | CureVac SE | Combinación de vacunación e inhibición de la trayectoria pd-1. |
| EP2968607B1 (en) | 2013-03-15 | 2019-07-24 | The Trustees Of The University Of Pennsylvania | Cancer vaccines and methods of treatment using the same |
| GB201315946D0 (en) | 2013-09-06 | 2013-10-23 | Immune Targeting Systems Its Ltd | Oncology vaccine |
| WO2015037000A1 (en) | 2013-09-11 | 2015-03-19 | Compugen Ltd | Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases |
| WO2015089114A1 (en) | 2013-12-09 | 2015-06-18 | Bullet Biotechnology, Inc. | Specific virus-like particle-cpg oligonucleotide vaccines and uses thereof |
| NZ721908A (en) | 2013-12-20 | 2022-12-23 | Massachusetts Gen Hospital | Combination therapy with neoantigen vaccine |
| US9903102B2 (en) | 2013-12-27 | 2018-02-27 | Xiamen Solex High-Tech Industries Co., Ltd. | Concealed embedded component for a waterway system |
| WO2015123496A1 (en) | 2014-02-14 | 2015-08-20 | Immune Design Corp. | Immunotherapy of cancer through combination of local and systemic immune stimulation |
| US10933106B2 (en) | 2014-02-25 | 2021-03-02 | Deutsches Krebsforschungszentrum | RNA viruses for immunovirotherapy |
| AU2015259510B2 (en) | 2014-05-13 | 2020-10-01 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| CA2946606C (en) | 2014-05-13 | 2023-06-06 | Bavarian Nordic A/S | Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3 |
| WO2016004213A2 (en) | 2014-07-01 | 2016-01-07 | Vicus Therapeutics, Llc | Hydrogels for treating and ameliorating cancers and potentiating the immune system and methods of making and using them |
| US20170196952A1 (en) | 2014-07-07 | 2017-07-13 | Duke University | Vaccines against an oncogenic isoform of esr1 and methods of using the same |
| WO2016007499A1 (en) | 2014-07-07 | 2016-01-14 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| EP3169355A4 (en) | 2014-07-18 | 2018-07-25 | Advaxis, Inc. | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
| US10759836B2 (en) | 2014-07-18 | 2020-09-01 | University Of Washington | Cancer vaccine compositions and methods of use thereof |
| US20170216403A1 (en) | 2014-08-12 | 2017-08-03 | Massachusetts Institute Of Technology | Synergistic tumor treatment with il-2, a therapeutic antibody, and an immune checkpoint blocker |
| CA2966132A1 (en) | 2014-10-23 | 2016-04-28 | Institut Gustave Roussy | Methods and products for modulating microbiota composition for improving the efficacy of a cancer treatment with an immune checkpoint blocker |
| EP3215182B1 (en) | 2014-11-05 | 2023-01-04 | The Regents of The University of California | Combination immunotherapy |
| KR20200109395A (ko) | 2016-01-19 | 2020-09-22 | 화이자 인코포레이티드 | 암 백신 |
| ES2965957T3 (es) | 2016-06-02 | 2024-04-17 | Ultimovacs Asa | Una vacuna junto con un inhibidor del punto de control inmunitario para usar en el tratamiento del cáncer |
| NL2017270B1 (en) | 2016-08-02 | 2018-02-09 | Aduro Biotech Holdings Europe B V | New anti-hCTLA-4 antibodies |
-
2017
- 2017-06-02 ES ES17729078T patent/ES2965957T3/es active Active
- 2017-06-02 US US16/306,352 patent/US11419927B2/en active Active
- 2017-06-02 AU AU2017275782A patent/AU2017275782B2/en not_active Ceased
- 2017-06-02 DK DK17729078.0T patent/DK3463436T3/da active
- 2017-06-02 WO PCT/EP2017/063589 patent/WO2017207814A1/en not_active Ceased
- 2017-06-02 SI SI201731461T patent/SI3463436T1/sl unknown
- 2017-06-02 PL PL17729078.0T patent/PL3463436T3/pl unknown
- 2017-06-02 HU HUE17729078A patent/HUE065176T2/hu unknown
- 2017-06-02 CA CA3026172A patent/CA3026172A1/en active Pending
- 2017-06-02 JP JP2018563076A patent/JP7321709B2/ja active Active
- 2017-06-02 FI FIEP17729078.0T patent/FI3463436T3/fi active
- 2017-06-02 PT PT177290780T patent/PT3463436T/pt unknown
- 2017-06-02 RS RS20231231A patent/RS65007B1/sr unknown
- 2017-06-02 EP EP23178501.5A patent/EP4253419A3/en active Pending
- 2017-06-02 EP EP17729078.0A patent/EP3463436B1/en active Active
- 2017-06-02 LT LTEPPCT/EP2017/063589T patent/LT3463436T/lt unknown
- 2017-06-02 HR HRP20231650TT patent/HRP20231650T1/hr unknown
-
2022
- 2022-08-09 US US17/818,584 patent/US12168045B2/en active Active
- 2022-08-24 JP JP2022132995A patent/JP2022171684A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3463436A1 (en) | 2019-04-10 |
| US12168045B2 (en) | 2024-12-17 |
| US20190247482A1 (en) | 2019-08-15 |
| JP2022171684A (ja) | 2022-11-11 |
| LT3463436T (lt) | 2024-01-25 |
| CA3026172A1 (en) | 2017-12-07 |
| EP3463436B1 (en) | 2023-09-20 |
| JP7321709B2 (ja) | 2023-08-07 |
| EP4253419A3 (en) | 2024-05-22 |
| JP2019517508A (ja) | 2019-06-24 |
| AU2017275782B2 (en) | 2024-08-15 |
| US11419927B2 (en) | 2022-08-23 |
| SI3463436T1 (sl) | 2024-02-29 |
| HUE065176T2 (hu) | 2024-05-28 |
| FI3463436T3 (fi) | 2023-12-04 |
| ES2965957T3 (es) | 2024-04-17 |
| DK3463436T3 (da) | 2023-12-18 |
| PT3463436T (pt) | 2023-12-28 |
| PL3463436T3 (pl) | 2024-03-04 |
| AU2017275782A1 (en) | 2019-01-24 |
| US20230049012A1 (en) | 2023-02-16 |
| RS65007B1 (sr) | 2024-01-31 |
| EP4253419A2 (en) | 2023-10-04 |
| WO2017207814A1 (en) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20231650T1 (hr) | Cjepivo u kombinaciji sa inhibitorom imunološke kontrolne točke za primjenu u liječenju raka | |
| AR104812A1 (es) | Combinaciones terapéuticas y métodos para tratar neoplasias | |
| EA202190669A1 (ru) | Процесс получения вакцинной композиции | |
| BR112017003194A2 (pt) | anticorpo ou fragmento de ligação ao antígeno do mesmo, composição, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, vacina, vaso ou dispositivo de injeção, e, métodos para antagonizar lag3 em um paciente humano que necessita do mesmo, para tratamento de um câncer em um indivíduo para administrar o anticorpo, o fragmento, a composição, o polipeptídeo, a vacina, o vetor ou o polinucleotídeo de ligação ao antígeno a um indivíduo, para produção de um anticorpo ou de um fragmento de ligação ao antígeno do mesmo ou polipeptídeo e para detectar a presença de um peptídeo lag3 ou de um fragmento do mesmo em uma amostra. | |
| AR106991A1 (es) | Anticuerpos neutralizantes del virus de inmunodeficiencia humana | |
| RU2017108173A (ru) | Комбинированная терапия на основе антител, активирующих человеческий cd40, и антител к человеческому pd-l1 | |
| JP2018501197A5 (cg-RX-API-DMAC7.html) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| SI2691112T1 (en) | STABILITY FORMULATION PROTITELES FOR HUMAN PROGRAMMED DEPRESSOR RECEPTOR PD-1 AND RELATED HEALTH | |
| HRP20201528T1 (hr) | Biparatopikalni polipeptidi koji antagoniziraju wnt signalizaciju u tumorskim stanicama | |
| BR112019008351A2 (pt) | imunoglobulinas e usos das mesmas | |
| MX2019006349A (es) | Proteinas recombinantes rsv f de prefusion nuevas y usos de las mismas. | |
| CO2020012621A2 (es) | Composiciones de proteína de fusión recombinante neuregulina-1 (nrg-1) humana y métodos para su uso | |
| JP2016527286A5 (cg-RX-API-DMAC7.html) | ||
| JP2019514998A5 (cg-RX-API-DMAC7.html) | ||
| SI3079715T1 (en) | A mixture of peptides | |
| HRP20212034T1 (hr) | Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe | |
| AR103896A1 (es) | Conjugados de fármacos de anticuerpos (adc) anti-proteínas flt3 | |
| EA201790341A1 (ru) | Анти-ск8 антитела для применения в лечении рака | |
| JP2019517508A5 (cg-RX-API-DMAC7.html) | ||
| MX2023008115A (es) | Terapia con receptores quiméricos. | |
| CL2020003292A1 (es) | Péptido que consiste en la secuencia de aminoácidos de seq id no: 2; anticuerpo que reconoce dicho péptido; receptor de linfocito t; célula hospedadora; linfocito t activado; composición farmacéutica; uso; y kit (divisional de la solicitud no. 201802969) | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| HRP20210207T1 (hr) | Uporaba protutijela anti-sklerostin u liječenju osteogenesis imperfecta | |
| IL240695B2 (en) | Nme inhibitors and methods of using nme inhibitors |